[
  {
    "ts": null,
    "headline": "Firm-Record Nine Dean Omar Branham Shirley Attorneys Recognized for Plaintiff Consumer Law Excellence",
    "summary": "DALLAS, February 18, 2026--In the wake of a record-breaking year on behalf of clients, nine attorneys with Dean Omar Branham Shirley (DOBS) have been named Lawdragon 500 Leading Plaintiff Consumer Lawyers for 2026.",
    "url": "https://finnhub.io/api/news?id=3154c17fdb6bf17be51f691d6ed0dc7e45cd3f653ea43d1bf4c6f93146207b01",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771447620,
      "headline": "Firm-Record Nine Dean Omar Branham Shirley Attorneys Recognized for Plaintiff Consumer Law Excellence",
      "id": 139139296,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "DALLAS, February 18, 2026--In the wake of a record-breaking year on behalf of clients, nine attorneys with Dean Omar Branham Shirley (DOBS) have been named Lawdragon 500 Leading Plaintiff Consumer Lawyers for 2026.",
      "url": "https://finnhub.io/api/news?id=3154c17fdb6bf17be51f691d6ed0dc7e45cd3f653ea43d1bf4c6f93146207b01"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
    "summary": "Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index decreasing 0",
    "url": "https://finnhub.io/api/news?id=74335c58137b18d75507ea6c93622d541a71079b1b5fb5cebefd44e5e6e8f3bf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771447563,
      "headline": "Sector Update: Health Care Stocks Decline Late Afternoon",
      "id": 139139297,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Health care stocks were lower late Wednesday afternoon, with the NYSE Health Care Index decreasing 0",
      "url": "https://finnhub.io/api/news?id=74335c58137b18d75507ea6c93622d541a71079b1b5fb5cebefd44e5e6e8f3bf"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Balances Oncology Breakthrough With Rising Talc Litigation Risk",
    "summary": "Johnson & Johnson (NYSE:JNJ) received FDA Breakthrough Therapy Designation for subcutaneous amivantamab as a monotherapy in recurrent or metastatic head and neck squamous cell carcinoma. In a separate development, a jury reached a verdict against Johnson & Johnson in a talc related ovarian cancer case, the first in a series of upcoming trials involving thousands of lawsuits. These events highlight both the progress of J&J's oncology pipeline and potential shifts in its legal exposure and...",
    "url": "https://finnhub.io/api/news?id=90122278538c7fe069226c45f9402bf644e15e005ffea82bd1359ddeeeace564",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771441853,
      "headline": "Johnson & Johnson Balances Oncology Breakthrough With Rising Talc Litigation Risk",
      "id": 139138625,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (NYSE:JNJ) received FDA Breakthrough Therapy Designation for subcutaneous amivantamab as a monotherapy in recurrent or metastatic head and neck squamous cell carcinoma. In a separate development, a jury reached a verdict against Johnson & Johnson in a talc related ovarian cancer case, the first in a series of upcoming trials involving thousands of lawsuits. These events highlight both the progress of J&J's oncology pipeline and potential shifts in its legal exposure and...",
      "url": "https://finnhub.io/api/news?id=90122278538c7fe069226c45f9402bf644e15e005ffea82bd1359ddeeeace564"
    }
  },
  {
    "ts": null,
    "headline": "Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues",
    "summary": "HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.",
    "url": "https://finnhub.io/api/news?id=e3a59d7d45a06f5969338430781457496b51edba2ce7f5f24c593072a121b39a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771431420,
      "headline": "Halozyme's Q4 Earnings Miss, Higher Royalties Drive Y/Y Revenues",
      "id": 139138626,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "HALO swings to Q4 loss on acquisition charge, but revenues surge 52%, fueled by royalties and product sales and top estimates.",
      "url": "https://finnhub.io/api/news?id=e3a59d7d45a06f5969338430781457496b51edba2ce7f5f24c593072a121b39a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory",
    "summary": "The facility is part of the company’s plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.",
    "url": "https://finnhub.io/api/news?id=03a476fd0cef31ab6b1939d80b58d2dd19bb7d1569e81aa5d90e26058a9ed02a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771429440,
      "headline": "Johnson & Johnson to Invest More Than $1 Billion in Pennsylvania Cell Therapy Factory",
      "id": 139137808,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The facility is part of the company’s plans to invest $55 billion in U.S. manufacturing, research and development and technology through early 2029.",
      "url": "https://finnhub.io/api/news?id=03a476fd0cef31ab6b1939d80b58d2dd19bb7d1569e81aa5d90e26058a9ed02a"
    }
  },
  {
    "ts": null,
    "headline": "J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push",
    "summary": "Feb 18 (Reuters) - Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale",
    "url": "https://finnhub.io/api/news?id=8e540301903a55b8bb3c63811aadf92bac21eed0b4a2e26f17417a31bbab409a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771428105,
      "headline": "J&J to invest $1 billion in new Pennsylvania plant amid US manufacturing push",
      "id": 139136581,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Feb 18 (Reuters) - Johnson & Johnson said on Wednesday it will invest more than $1 billion to build a new cell therapy facility in Pennsylvania, part of its larger plans announced last year to scale",
      "url": "https://finnhub.io/api/news?id=8e540301903a55b8bb3c63811aadf92bac21eed0b4a2e26f17417a31bbab409a"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania",
    "summary": "NEW BRUNSWICK, N.J., February 18, 2026--Johnson & Johnson (NYSE: JNJ) (the \"Company\"), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neuro",
    "url": "https://finnhub.io/api/news?id=cbc6e57af0f09ad2aa193a788ee02c6008254bf90cf6bdb7a36a5be8723c88b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771427700,
      "headline": "Johnson & Johnson Expands U.S. Footprint with more than $1 Billion Investment in Next Generation Cell Therapy Manufacturing Facility in Pennsylvania",
      "id": 139136599,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "NEW BRUNSWICK, N.J., February 18, 2026--Johnson & Johnson (NYSE: JNJ) (the \"Company\"), healthcare’s leading, most comprehensive innovation powerhouse, today announced a more than $1 billion investment in a next generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. This new facility will further expand the Company’s U.S. manufacturing capacity as it advances its industry leading portfolio and pipeline of transformational medicines for cancer, immune-mediated and neuro",
      "url": "https://finnhub.io/api/news?id=cbc6e57af0f09ad2aa193a788ee02c6008254bf90cf6bdb7a36a5be8723c88b1"
    }
  },
  {
    "ts": null,
    "headline": "Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?",
    "summary": "Verizon (NYSE: VZ) and Johnson & Johnson (NYSE: JNJ) both rewarded shareholders with dividend increases this quarter, but their paths to sustaining those payouts look very different. Verizon raised its quarterly dividend to $0.69 per share, marking its 19th consecutive annual raise. Johnson & Johnson lifted its quarterly payout to $1.30 per share, extending a ... Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?",
    "url": "https://finnhub.io/api/news?id=d4fc0a35a33f6ac3fa85801c747589c9467e3d193dd70d2157fc621b0b948b93",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771424155,
      "headline": "Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?",
      "id": 139136600,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Verizon (NYSE: VZ) and Johnson & Johnson (NYSE: JNJ) both rewarded shareholders with dividend increases this quarter, but their paths to sustaining those payouts look very different. Verizon raised its quarterly dividend to $0.69 per share, marking its 19th consecutive annual raise. Johnson & Johnson lifted its quarterly payout to $1.30 per share, extending a ... Verizon vs Johnson & Johnson: Which Dividend Hike Winner Is the Better Buy?",
      "url": "https://finnhub.io/api/news?id=d4fc0a35a33f6ac3fa85801c747589c9467e3d193dd70d2157fc621b0b948b93"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=d1bd161805ac19fdc20274cf6f931be0fbdba51c512207a36f1748b204769fdc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771423206,
      "headline": "Johnson & Johnson (JNJ) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 139137809,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Johnson & Johnson (JNJ) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=d1bd161805ac19fdc20274cf6f931be0fbdba51c512207a36f1748b204769fdc"
    }
  },
  {
    "ts": null,
    "headline": "Is Kenvue (KVUE) Attractively Priced After Spin Off From Johnson & Johnson?",
    "summary": "If you are wondering whether Kenvue's current share price lines up with its underlying value, you are not alone, this article breaks down what the market might be pricing in. The stock last closed at US$18.41, with returns of 0.5% over 7 days, 7.0% over 30 days, 6.3% year to date and a 12.7% decline over the past year, which gives a mixed picture of recent sentiment. Recent headlines have focused on Kenvue's position as a standalone consumer health company following its separation from...",
    "url": "https://finnhub.io/api/news?id=751339f37b015e0a36ee0ef813bee604d04b7f3256344edfb0289e04715a66e9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771416553,
      "headline": "Is Kenvue (KVUE) Attractively Priced After Spin Off From Johnson & Johnson?",
      "id": 139134040,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "If you are wondering whether Kenvue's current share price lines up with its underlying value, you are not alone, this article breaks down what the market might be pricing in. The stock last closed at US$18.41, with returns of 0.5% over 7 days, 7.0% over 30 days, 6.3% year to date and a 12.7% decline over the past year, which gives a mixed picture of recent sentiment. Recent headlines have focused on Kenvue's position as a standalone consumer health company following its separation from...",
      "url": "https://finnhub.io/api/news?id=751339f37b015e0a36ee0ef813bee604d04b7f3256344edfb0289e04715a66e9"
    }
  },
  {
    "ts": null,
    "headline": "XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500",
    "summary": "Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of market conditions. Health Care Select Sector SPDR Fund (NYSEARCA:XLV) offers concentrated exposure to this defensive sector, but with concentration comes tradeoffs investors must understand before allocating capital. Pure Healthcare Exposure With Mega-Cap Anchors XLV functions ... XLV is A $41 Billion Defensive Healthcare Play That Looks",
    "url": "https://finnhub.io/api/news?id=d88d9891829ddb340cf72a3b311e050a1ba7b49790128751ab2509b9b5f4faf7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771410775,
      "headline": "XLV is A $41 Billion Defensive Healthcare Play That Looks Good Until You Compare To The S&P 500",
      "id": 139132609,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Healthcare isn’t going anywhere. An aging population, chronic disease management, and breakthrough treatments ensure this sector remains essential regardless of market conditions. Health Care Select Sector SPDR Fund (NYSEARCA:XLV) offers concentrated exposure to this defensive sector, but with concentration comes tradeoffs investors must understand before allocating capital. Pure Healthcare Exposure With Mega-Cap Anchors XLV functions ... XLV is A $41 Billion Defensive Healthcare Play That Looks",
      "url": "https://finnhub.io/api/news?id=d88d9891829ddb340cf72a3b311e050a1ba7b49790128751ab2509b9b5f4faf7"
    }
  },
  {
    "ts": null,
    "headline": "IXJ: Healthcare Sector Dashboard For February",
    "summary": "IXJ: Healthcare Sector Dashboard For February",
    "url": "https://finnhub.io/api/news?id=4c7217c375ec3588b7d733d67e76ed36acfbee5d367368b6809a501d5b536ff7",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771408800,
      "headline": "IXJ: Healthcare Sector Dashboard For February",
      "id": 139136343,
      "image": "",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=4c7217c375ec3588b7d733d67e76ed36acfbee5d367368b6809a501d5b536ff7"
    }
  },
  {
    "ts": null,
    "headline": "FDA chief Marty Makary says 'everything should be over the counter' unless drug is unsafe or addictive",
    "summary": "Makary said the FDA is looking at prescription drugs like nausea medications and vaginal estrogen, and hopes to make changes this year.",
    "url": "https://finnhub.io/api/news?id=04105639750ceec82f927ba72ef6ce83266b0d6af2f1fef117a869390c1457e0",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771404877,
      "headline": "FDA chief Marty Makary says 'everything should be over the counter' unless drug is unsafe or addictive",
      "id": 139137337,
      "image": "https://image.cnbcfm.com/api/v1/image/108111981-17412749682025-03-06t152858z_1041948067_rc2r7da7wjpm_rtrmadp_0_usa-trump-fda.jpeg?v=1741274989&w=1920&h=1080",
      "related": "JNJ",
      "source": "CNBC",
      "summary": "Makary said the FDA is looking at prescription drugs like nausea medications and vaginal estrogen, and hopes to make changes this year. ",
      "url": "https://finnhub.io/api/news?id=04105639750ceec82f927ba72ef6ce83266b0d6af2f1fef117a869390c1457e0"
    }
  },
  {
    "ts": null,
    "headline": "Johnson & Johnson Announce Breakthrough Therapy Designation From FDA For RYBREVANT In Non-Small Cell Lung Cancer",
    "summary": "Johnson & Johnson Announce Breakthrough Therapy Designation From FDA For RYBREVANT In Non-Small Cell Lung Cancer",
    "url": "https://finnhub.io/api/news?id=5b8e0eb934c90c188661a5a020370db6df8347b232af8875a6c407f26bdb9f03",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771403812,
      "headline": "Johnson & Johnson Announce Breakthrough Therapy Designation From FDA For RYBREVANT In Non-Small Cell Lung Cancer",
      "id": 139135050,
      "image": "",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=5b8e0eb934c90c188661a5a020370db6df8347b232af8875a6c407f26bdb9f03"
    }
  },
  {
    "ts": null,
    "headline": "Trellus Health Extends Johnson & Johnson Collaboration Through Mid-2026 On Same Economic Terms After Achieving Key Engagement And Satisfaction Metrics",
    "summary": "Trellus Health Extends Johnson & Johnson Collaboration Through Mid-2026 On Same Economic Terms After Achieving Key Engagement And Satisfaction Metrics",
    "url": "https://finnhub.io/api/news?id=7984c214a1ae08a5ef83cb1f874e7e765a0ceb1f6eb9f881552f5ac82573b518",
    "source": "Benzinga",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771386404,
      "headline": "Trellus Health Extends Johnson & Johnson Collaboration Through Mid-2026 On Same Economic Terms After Achieving Key Engagement And Satisfaction Metrics",
      "id": 139133566,
      "image": "",
      "related": "JNJ",
      "source": "Benzinga",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=7984c214a1ae08a5ef83cb1f874e7e765a0ceb1f6eb9f881552f5ac82573b518"
    }
  },
  {
    "ts": null,
    "headline": "This State Has More Millionaires Per Capita Than Any Other",
    "summary": "There are many ways to describe America. Some might call it a veritable patchwork of diverse cultures and social strata. That’s a fancy way of saying that prosperity is concentrated in some U.S. states more than in others. As a result, a handful of America’s 50 states have more millionaires than others. By the process ... This State Has More Millionaires Per Capita Than Any Other",
    "url": "https://finnhub.io/api/news?id=0b69ba08e8438c795b2a5c5ba414e722c5a52abf4d7d7d1c6eaa471cfa88f4ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1771381280,
      "headline": "This State Has More Millionaires Per Capita Than Any Other",
      "id": 139129002,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "There are many ways to describe America. Some might call it a veritable patchwork of diverse cultures and social strata. That’s a fancy way of saying that prosperity is concentrated in some U.S. states more than in others. As a result, a handful of America’s 50 states have more millionaires than others. By the process ... This State Has More Millionaires Per Capita Than Any Other",
      "url": "https://finnhub.io/api/news?id=0b69ba08e8438c795b2a5c5ba414e722c5a52abf4d7d7d1c6eaa471cfa88f4ed"
    }
  }
]